United Therapeutics moved to broaden its cell-therapy pipeline by paying $140 million to acquire Thymmune Therapeutics, targeting thymus-derived regenerative approaches. The upfront payment is paired with up to $160 million in milestones, with additional payments tied to clinical and regulatory progress through 2031. Thymmune is developing THY-100, a process converting human iPSCs into thymic cells intended to create a “neo-thymus.” Its near-term indication is congenital athymia, an ultra-rare condition with historically poor survival outcomes; United’s rationale includes scalability and a longer-term roadmap that could extend beyond the ultra-rare setting. The deal also points to continued investor and operator interest in organ-development and tolerance-focused cell approaches as companies look beyond conventional biologics.